Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090342 | 0.76 | ROCK1 (0.39) | ROCK1 | |
| SCHEMBL11938729 | 0.75 | ROCK1 (0.39) | ROCK1MAPK8 | |
| SCHEMBL5096293 | 0.74 | ROCK1 (0.51) | ROCK1MAPK8 | |
| SCHEMBL2510492 | 0.74 | ROCK1 (0.38) | ROCK1MAPK8 | |
| SCHEMBL14768213 | 0.73 | MAPK8 (0.58) | MAPK8 | |
| SCHEMBL14175898 | 0.73 | MAPK8 (0.58) | MAPK8 | |
| SCHEMBL14193105 | 0.71 | ROCK1 (0.36) | ROCK1MAPK8 | |
| SCHEMBL5095954 | 0.70 | MAPK8 (0.57) | ROCK1MAPK8 | |
| SCHEMBL5102030 | 0.70 | CDC7 (0.38) | ROCK1 | |
| SCHEMBL28179643 | 0.70 | CDK2 (0.58) | ROCK1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | ROCK1 497/4885MAPK8 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.